Zobrazeno 1 - 10
of 546
pro vyhledávání: '"JUNJI FURUSE"'
Autor:
Mitsuhiro Furuta, Kei Hayashi, Mamoru Watanabe, Takanori Hama, Misa Onishi, Kyoko Furusawa, Yasuhiro Inokuchi, Akifumi Notsu, Nozomu Machida, Junji Furuse, Shin Maeda
Publikováno v:
BMC Gastroenterology, Vol 24, Iss 1, Pp 1-10 (2024)
Abstract Background The post-insertion clinical course of esophageal self-expandable metal stents (SEMS) in initially frail patients with esophageal carcinoma (EC) with dysphagia remains unclear. This study aimed to assess dysphagia improvement and e
Externí odkaz:
https://doaj.org/article/4ebe3e28861f4bebb4dcf1602006f559
Autor:
Satoshi Kobayashi, Shun Tezuka, Yui Yamachika, Shotaro Tsunoda, Shuhei Nagashima, Yuichiro Tozuka, Taito Fukushima, Manabu Morimoto, Makoto Ueno, Junji Furuse, Shin Maeda
Publikováno v:
BMC Cancer, Vol 23, Iss 1, Pp 1-8 (2023)
Abstract Background Fluorouracil, leucovorin (5FU/LV), and nanoliposomal-irinotecan (nal-IRI) combination therapy has been established as the second-line treatment for advanced pancreatic ductal adenocarcinoma. Oxaliplatin with 5FU/LV (FOLFOX) is oft
Externí odkaz:
https://doaj.org/article/9f393b00e3684232980b379d7f04bd55
Autor:
Junji Furuse, Namiki Izumi, Kenta Motomura, Yoshitaka Inaba, Yoshio Katamura, Yasuteru Kondo, Kazuhisa Yabushita, Katsuaki Motoyoshi, Masatoshi Kudo
Publikováno v:
Drugs - Real World Outcomes, Vol 10, Iss 2, Pp 195-205 (2023)
Abstract Background Lenvatinib was approved for use in unresectable hepatocellular carcinoma (uHCC) in Japan in 2018. Patients with diverse clinical characteristics receive lenvatinib treatment in clinical practice. Thus, it is crucial to evaluate th
Externí odkaz:
https://doaj.org/article/1586272cd8f54a5590c0cca0a2b18019
Autor:
Masatoshi Kudo, Kazuomi Ueshima, Issei Saeki, Toru Ishikawa, Yoshitaka Inaba, Naoki Morimoto, Hiroshi Aikata, Nobukazu Tanabe, Yoshiyuki Wada, Yasuteru Kondo, Masahiro Tsuda, Kazuhiko Nakao, Takanori Ito, Tetsuya Hosaka, Yusuke Kawamura, Teiji Kuzuya, Shunsuke Nojiri, Chikara Ogawa, Hironori Koga, Keisuke Hino, Masafumi Ikeda, Michihisa Moriguchi, Takashi Hisai, Kenichi Yoshimura, Junji Furuse, Yasuaki Arai
Publikováno v:
Liver Cancer (2023)
Background: Transarterial chemoembolization (TACE) is the standard treatment for unresectable intermediate-stage hepatocellular carcinoma (HCC), but recurrence after TACE is common. The present phase II, prospective, multicenter, single-arm trial, th
Externí odkaz:
https://doaj.org/article/48f623fe69374965a18cf38cb68f57fa
Autor:
Ikuhiro Yamada, Chigusa Morizane, Takuji Okusaka, Junki Mizusawa, Tomoko Kataoka, Makoto Ueno, Masafumi Ikeda, Naohiro Okano, Akiko Todaka, Satoshi Shimizu, Nobumasa Mizuno, Mitsugu Sekimoto, Kazutoshi Tobimatsu, Hironori Yamaguchi, Tomohiro Nishina, Hirofumi Shirakawa, Yasushi Kojima, Takamasa Oono, Yasuyuki Kawamoto, Masayuki Furukawa, Tomohisa Iwai, Kentaro Sudo, Keiya Okamura, Tatsuya Yamashita, Naoya Kato, Kazuhiko Shioji, Kyouko Shimizu, Toshio Nakagohri, Ken Kamata, Hiroshi Ishii, Junji Furuse, JCOG-HBPOG
Publikováno v:
Scientific Reports, Vol 12, Iss 1, Pp 1-9 (2022)
Abstract In the FUGA-BT trial (JCOG1113), gemcitabine plus S-1 (GS) showed non-inferiority to gemcitabine plus cisplatin (GC) in overall survival (OS) with good tolerance for patients with advanced biliary tract cancer (BTC). We performed a subgroup
Externí odkaz:
https://doaj.org/article/1549f8218db94a0d8c1d083f2ead51f8
Autor:
David Goldstein, Richard Hubner, Angela Lamarca, Lipika Goyal, Junji Furuse, Tanios Bekaii-Saab, Jennifer Knox, Mairéad G McNamara, Juan Valle, Rachna Shroff, Chigusa Morizane, Lorenza Rimassa, John Bridgewater, Timothy Jacobs, Anna D Wagner, Markus Moehler, Maeve Lowery, Robin K Kelley
Publikováno v:
BMJ Open, Vol 12, Iss 10 (2022)
Objectives Female physicians in medicine are increasing, but disparities in female authorship exist. The aim of this study was to characterise factors associated with female first (FF) and female senior (SF) authorship in later phase systemic oncolog
Externí odkaz:
https://doaj.org/article/01c4ef9a216d47869af0aedf52dbfa7c
Autor:
Masafumi Ikeda, Tatsuya Yamashita, Sadahisa Ogasawara, Masatoshi Kudo, Yoshitaka Inaba, Manabu Morimoto, Kaoru Tsuchiya, Satoshi Shimizu, Yasushi Kojima, Atsushi Hiraoka, Kazuhiro Nouso, Hiroshi Aikata, Kazushi Numata, Tosiya Sato, Takuji Okusaka, Junji Furuse
Publikováno v:
Liver Cancer, Pp 1-1 (2023)
Introduction: Hepatic arterial infusion chemotherapy (HAIC) with cisplatin and lenvatinib exhibits strong antitumor effects against advanced hepatocellular carcinoma (HCC). Higher antitumor activity is expected for the combination treatment. The aim
Externí odkaz:
https://doaj.org/article/70ed082b71044c7295016b508d1cb9b3
Autor:
Makoto Ueno, Chigusa Morizane, Takuji Okusaka, Junki Mizusawa, Tomoko Kataoka, Masafumi Ikeda, Masato Ozaka, Naohiro Okano, Kazuya Sugimori, Akiko Todaka, Satoshi Shimizu, Nobumasa Mizuno, Tomohisa Yamamoto, Keiji Sano, Kazutoshi Tobimatsu, Akio Katanuma, Atsushi Miyamoto, Hironori Yamaguchi, Tomohiro Nishina, Hirofumi Shirakawa, Yasushi Kojima, Takamasa Oono, Yasuyuki Kawamoto, Masayuki Furukawa, Tomohisa Iwai, Kentaro Sudo, Hiroyuki Miyakawa, Tatsuya Yamashita, Ichirou Yasuda, Hidenori Takahashi, Naoya Kato, Kazuhiko Shioji, Kyoko Shimizu, Toshio Nakagohri, Ken Kamata, Hiroshi Ishii, Junji Furuse, the members of the Hepatobiliary and Pancreatic Oncology Group of the Japan Clinical Oncology Group (JCOG-HBPOG).
Publikováno v:
Scientific Reports, Vol 11, Iss 1, Pp 1-9 (2021)
Abstract JCOG1113 is a randomized phase III trial in patients with advanced biliary tract cancers (BTCs) (UMIN000001685), and gemcitabine plus S-1 (GS) was not inferior to gemcitabine plus cisplatin (GC). However, poor renal function often results in
Externí odkaz:
https://doaj.org/article/fb2d299674634abea61faf256923e408
Autor:
Matthew Ledenko, Samuel O. Antwi, Shiho Arima, Julia Driscoll, Junji Furuse, Heinz-Josef Klümpen, Finn Ole Larsen, David K. Lau, Annett Maderer, Alice Markussen, Markus Moehler, Lynn E. Nooijen, Walid L. Shaib, Niall C. Tebbutt, Thierry André, Makoto Ueno, Rachel Woodford, Changhoon Yoo, Mark M. Zalupski, Tushar Patel
Publikováno v:
Frontiers in Oncology, Vol 12 (2022)
Externí odkaz:
https://doaj.org/article/d600a4255c654614935a6f7f40a8171d
Autor:
Masatoshi Kudo, Kenta Motomura, Yoshiyuki Wada, Yoshitaka Inaba, Yasunari Sakamoto, Masayuki Kurosaki, Yoshiko Umeyama, Yoichi Kamei, Junichiro Yoshimitsu, Yosuke Fujii, Mana Aizawa, Paul B. Robbins, Junji Furuse
Publikováno v:
Liver Cancer, Pp 1-11 (2021)
Introduction: Combining an immune checkpoint inhibitor with a targeted antiangiogenic agent may leverage complementary mechanisms of action for the treatment of advanced/metastatic hepatocellular carcinoma (aHCC). Avelumab is a human anti-PD-L1 IgG1
Externí odkaz:
https://doaj.org/article/b8be2ef681554e6887c3892833ec2d08